Related Experiment Video
Updated: May 26, 2026

Flexible Colonoscopy in Mice to Evaluate the Severity of Colitis and Colorectal Tumors Using a Validated Endoscopic Scoring System
Published on: October 16, 2013
The UCEIS and UC-100 score were responsive endoscopic and global indices in a phase 2 trial of ulcerative colitis
Sudheer K Vuyyuru1,2, Simon Travis3, Soushyant Kiarasi1
1Alimentiv Inc., London, ON, Canada.
Background:
Trials evaluating ulcerative colitis (UC) therapies necessitate instruments that are responsive to changes in disease status. We assessed responsiveness of the Mayo Endoscopic Subscore (MES), Ulcerative Colitis Endoscopic Index of Severity (UCEIS), Robarts Histopathology Index (RHI), Geboes Score (GS), Nancy Histological Index (NHI), and UC-100 score.
Methods:
Using data from a phase 2 placebo-controlled trial of mirikizumab, responsiveness was quantified by the probability that a patient in the treatment group would have a better score than (win over) a control patient. Inference on win probability (WinP) was conducted without normality assumption of scores. Spearman rank correlations between each index and stool frequency (SF), rectal bleeding (RB), fecal calprotectin (FCAL), and C-reactive protein (CRP) were assessed.
Results:
WinP estimates showed that magnitudes of responsiveness were "medium" for the UCEIS (0.67; 95% CI 0.59, 0.74) and UC-100 score (0.68; 95% CI 0.60, 0.75) and "small" for the RHI (0.62; 95% CI 0.54, 0.70), MES (0.61; 95% CI 0.53, 0.68), and GS (0.60; 95% CI 0.52, 0.68). The NHI showed no statistical evidence of responsiveness (0.57; 95% CI 0.48, 0.65). The UCEIS and MES had weak-to-moderate correlations with SF (0.21-0.26) and RB (0.29-0.33) but no correlation with biomarkers. The UC-100 had moderate correlations with RB (0.46) and FCAL (0.42) and weak correlation with CRP (0.19).
Conclusions:
The UCEIS and UC-100 score were responsive to changes in endoscopic and global UC disease activity, respectively. Results may help inform future early phase UC drug trials but should be confirmed in larger studies.
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Inflammatory Bowel Disease II: Ulcerative Colitis
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Urologic Endoscopic Procedure: Cystoscopic Examination

